Virogin reports on in vitro and in vivo research with VG-301 oncolytic virus

Feb. 9, 2023

Virogin Biotech Canada Ltd. has published research on its newest generation of an oncolytic virus product, VG-301 (VG-21306).

BioWorld Science Cancer Immuno-oncology Oncolytic

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 16, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Capsules and tablets scattered over a world map

Biopharma tariffs becoming more than a threat

BioWorld

U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an...

New Trump order zeroes in on drug prices

BioWorld

In a blast from the past, U.S. President Donald Trump signed an executive order April 15 to deliver on his 2016 campaign promises and strengthen or reinstate...